Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2023-03-03 Regulatory Filings
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings
2023-03-03 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 100% confidence The document is a Management Certification related to Form 13-502F1, which is a regulatory form submitted to the Ontario Securities Commission concerning participation fees for Class 1 and Class 3B reporting issuers. It includes detailed calculations of market values, capitalization, and fees payable. The document is primarily a certification by an officer confirming the accuracy and completeness of the information provided in the form. It does not contain financial statements, management discussion, or other report content but is a regulatory filing required by securities regulation. Therefore, it fits best under Regulatory Filings (RNS) as it is a certification and submission of regulatory information rather than a financial report or announcement.
2023-03-03 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the CEO. It certifies the review and fair presentation of the annual filings including the AIF, annual financial statements, and annual MD&A for the financial year ended October 31, 2022. The document is a certification letter and does not contain actual financial data or the full annual report itself. It explicitly states it is a certification under National Instrument 52-109 and does not include representations about internal controls. According to the CERTIFICATION RULE, such officer certifications referencing annual filings should be classified as Regulatory Filings (RNS), not as the Annual Report (10-K) or other report types. The document length is short (3111 characters), consistent with a certification letter rather than a full report. Therefore, the correct classification is Regulatory Filings (RNS).
2023-03-03 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV1 Certification of Annual Filings by the CFO of BioVaxys Technology Corp. It certifies the review and fair presentation of the annual filings including the AIF, annual financial statements, and annual MD&A for the financial year ended October 31, 2022. The document is a certification letter and does not contain actual financial data or the full annual report itself. It explicitly states it is a certification under National Instrument 52-109 for venture issuers, which is an officer attestation. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than the actual Annual Report (10-K) or Management Reports (MDA). The document length is short (3086 characters) and it is a standalone certification, not the full report or announcement of report publication. Therefore, the correct classification is Regulatory Filings (RNS).
2023-03-03 English
Annual MD&A - English.pdf
Regulatory Filings
2023-03-03 English
Other.pdf
M&A Activity Classification · 90% confidence The document is a Distribution Agreement between two companies, PROCARE HEALTH IBERIA, S.L. and BIOVAXYS. It details terms related to distribution rights, obligations, exclusivity, trademarks, purchase quantities, and other contractual clauses. There is no indication that this is a financial report, regulatory filing, earnings release, or any other type of corporate filing related to financial performance or governance. Instead, it is a commercial contract outlining the terms of distribution of products. Such agreements do not fall under the typical financial or regulatory filing categories but are often considered as part of M&A or transaction-related documents if related to business arrangements. Given the nature of the document as a contractual agreement related to distribution rights and obligations, the most appropriate classification is M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids and related business agreements. Confidence is high as the document clearly is a distribution agreement and not a financial or regulatory report.
2022-12-20 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.